Sikander Ailawadhi, MD

Sikander Ailawadhi, MD, reviews patient experience and satisfaction findings from the phase 3 IRAKLIA study comparing subcutaneous isatuximab via on-body injector with intravenous isatuximab in relapsed or refractory multiple myeloma.

Ailawadhi and Faiman discuss the rationale for efforts to bring isatuximab on-body injectors into the clinic for patients with multiple myeloma.

Sikander Ailawadhi, MD, discusses early efficacy and safety data for iopofosine I 131 monotherapy in Waldenström macroglobulinemia.

Sikander Ailawadhi, MD, discusses non-BCMA CAR T-cell therapies currently under investigation in multiple myeloma.

Sikander Ailawadhi, MD, shares considerations for the potential sequencing of bispecific antibodies and other BCMA-directed therapies in multiple myeloma.

Sikander Ailawadhi, MD, oncologist, Department of Hematology, CAR T-Cell Therapy Program, Mayo Clinic, discusses how the investigational agent iopofosine I-131 may address unmet needs for patients with Waldenström macroglobulinemia.

Dr Joseph Mikhael and expert panel re-visit the patient case and offer their final thoughts on the impact of clinical trial updates in the treatment landscape of multiple myeloma.

Dr Joseph Mikhael and expert panel discuss key efficacy and safety outcomes of pivotal clinical trials evaluating treatment regimens in patients with R/R multiple myeloma.

Dr Joseph Mikhael and expert panel review current treatment options for patients with early relapse multiple myeloma, in accordance with current NCCN guidelines.

Dr Joseph Mikhael and expert panel review a case study in early relapse multiple myeloma and the impact of cytogenetics in risk assessment for patients with early relapse multiple myeloma.

Joseph Mikhael, MD, discusses diagnosis criteria and treatment considerations for patients with multiple myeloma in the frontline setting.

Expert panelists share their closing thoughts on the path to improve health equity in multiple myeloma management for racial and ethnic minority groups.

Joint consideration for physician bias in the management of multiple myeloma and how it can be addressed while treating patients belonging to racial and ethnic minority groups.

Centering discussion clinical trials in multiple myeloma, panelists review how to improve access to these studies for racial and ethnic minority groups.

Experts on multiple myeloma share comprehensive insight on how to build better access to specialty care for patients of racial and ethnic minority groups.

Expert perspectives on how to improve the early detection of multiple myeloma within patients belonging to racial and ethnic minority groups.

Closing out their review of the barriers racial and ethnic minority groups encounter in receiving care, expert panelists address access to transplantation or novel therapy.

Comprehensive discussion on access to specialized care and how racial and ethnic minority groups encounter barriers in this setting.

Panelists address how racial and ethnic minority groups experience disparity in time to diagnosis within the multiple myeloma treatment pathway.

Expert panelists shift their attention to how social determinants of multiple myeloma impact the treatment received by racial and ethnic minority groups.

Focused discussion on the biological determinants of multiple myeloma and how its prevalence is reflected in racial and ethnic minority groups.

Joseph Mikhael, MD, spearheads an overview on the prevalence of multiple myeloma in racial and ethnic minority groups in the context of health equity.

Sikander Ailawadhi, MD, discusses the examination of iopofosine I-131 (CLR 131) in Waldenström macroglobulinemia.

Sikander Ailawadhi, MD, discusses the rationale for evaluating lisaftoclax in chronic lymphocytic leukemia in an early phase 1 study.

Sikander Ailawadhi, MD, discusses the next steps with lisaftoclax in chronic lymphocytic leukemia and other hematologic malignancies.

Sikander Ailawadhi, MD, discusses the results of a first-in-human, early phase 1 study of lisaftoclax in patients with hematologic malignancies.

Sikander Ailawadhi, MD, discusses patient considerations for BTK inhibitors in Waldenström macroglobulinemia.

Sikander Ailawadhi, MD, discusses the next steps with lisaftoclax in chronic lymphocytic leukemia.

Sikander Ailawadhi, MD, discusses the safety profile of lisaftoclax in chronic lymphocytic leukemia.

Sikander Ailawadhi, MD, discusses the rationale to evaluate lisaftoclax in chronic lymphocytic leukemia.